​

UroGen Pharma (URGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

URGN Stock Forecast

UroGen Pharma (URGN) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $56.60, with a high of $75.00 and a low of $44.00. This represents a 25.78% increase from the last price of $45.00.

$10 $23 $36 $49 $62 $75 High: $75 Avg: $56.6 Low: $44 Last Closed Price: $45

URGN Stock Rating

UroGen Pharma stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (75.00%), 4 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 4 12 Strong Sell Sell Hold Buy Strong Buy

URGN Price Target Upside V Benchmarks

TypeNameUpside
StockUroGen Pharma25.78%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts168
Avg Price Target$56.00$54.17$51.25
Last Closing Price$45.00$45.00$45.00
Upside/Downside24.44%20.38%13.89%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26161--8
Aug, 26161--8
Jul, 26151--7
Jun, 26161--8
May, 26161--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2026Amin MakaremJefferies$56.00$45.0024.44%24.44%
Aug 06, 2026Michael SchmidtGuggenheim$58.00$46.4324.92%28.89%
Aug 06, 2026H.C. Wainwright$75.00$46.4361.53%66.67%
Jul 21, 2026Guggenheim$42.00$42.88-2.05%-6.67%
Jul 16, 2026Leland GershellOppenheimer$50.00$39.8025.63%11.11%
Jul 15, 2026Goldman Sachs$44.00$39.8010.55%-2.22%
May 11, 2026Raghuram SelvarajuH.C. Wainwright$45.00$29.4053.06%-
Apr 09, 2026Amin MakaremJefferies$40.00$20.5394.84%-11.11%
Jun 13, 2025Paul ChoiGoldman Sachs$16.00$12.0333.00%-64.44%
Jun 13, 2025Leland GershellOppenheimer$31.00$12.03157.69%-31.11%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 10, 2026JefferiesBuyBuyhold
Aug 06, 2026H.C. WainwrightBuyBuyhold
Aug 05, 2026Cowen & Co.BuyBuyhold
Jul 21, 2026GuggenheimBuyBuyhold
Jul 16, 2026OppenheimerOutperformOutperformhold
Jul 15, 2026Goldman SachsNeutralNeutralhold
Jul 09, 2026UBSBuyBuyhold
Jun 03, 2026H.C. WainwrightBuyBuyhold
Jun 02, 2026OppenheimerOutperformOutperformhold
May 11, 2026H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.96$-4.79$-3.55$-2.96$-3.19---
Avg Forecast$-4.82$-4.52$-3.56$-3.14$-2.68$-0.44$2.54$3.80
High Forecast$-4.01$-4.03$-3.45$-3.05$-1.84$2.91$4.36$4.38
Low Forecast$-5.48$-5.01$-3.64$-3.23$-4.15$-6.48$0.80$3.29
Surprise %2.90%5.97%-0.28%-5.73%19.03%---

Revenue Forecast

$0 $130M $260M $390M $520M $650M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$48.04M$64.36M$82.71M$90.40M$109.79M---
Avg Forecast$48.11M$64.78M$81.75M$90.94M$133.00M$274.70M$494.08M$579.86M
High Forecast$53.16M$70.22M$82.20M$91.75M$142.82M$277.16M$552.35M$648.24M
Low Forecast$41.85M$59.38M$81.30M$90.12M$123.19M$272.24M$443.44M$520.42M
Surprise %-0.13%-0.66%1.18%-0.59%-17.46%---

Net Income Forecast

$-200M $-130M $-60M $10M $80M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-110.82M$-109.78M$-102.24M$-126.87M$-153.49M---
Avg Forecast$-139.03M$-130.28M$-102.24M$-90.50M$-115.51M$25.79M$74.39M$109.47M
High Forecast$-115.54M$-116.15M$-99.57M$-87.87M$-52.96M$83.81M$125.72M$126.26M
Low Forecast$-158.04M$-144.50M$-105.09M$-93.13M$-119.77M$-186.90M$23.07M$94.89M
Surprise %-20.29%-15.73%-40.19%32.89%---

URGN Forecast FAQ

Is UroGen Pharma stock a buy?

UroGen Pharma stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that UroGen Pharma is a favorable investment for most analysts.

What is UroGen Pharma's price target?

UroGen Pharma's price target, set by 16 Wall Street analysts, averages $56.6 over the next 12 months. The price target range spans from $44 at the low end to $75 at the high end, suggesting a potential 25.78% change from the previous closing price of $45.

How does UroGen Pharma stock forecast compare to its benchmarks?

UroGen Pharma's stock forecast shows a 25.78% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for UroGen Pharma over the past three months?

  • September 2026: 12.50% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 12.50% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 14.29% Strong Buy, 71.43% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is UroGen Pharma’s EPS forecast?

UroGen Pharma's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.44, marking a -86.21% decrease from the reported $-3.19 in 2025. Estimates for the following years are $2.54 in 2027, and $3.8 in 2028.

What is UroGen Pharma’s revenue forecast?

UroGen Pharma's average annual revenue forecast for its fiscal year ending in December 2026 is $274.7M, reflecting a 150.21% increase from the reported $109.79M in 2025. The forecast for 2027 is $494.08M, and $579.86M for 2028.

What is UroGen Pharma’s net income forecast?

UroGen Pharma's net income forecast for the fiscal year ending in December 2026 stands at $25.79M, representing a -116.80% decrease from the reported $-153M in 2025. Projections indicate $74.39M in 2027, and $109.47M in 2028.